Independent prognostic value of KRAS mutation in resected colorectal cancer based on multi-gene sequencing

Table 4 Association between TP53 mutation status and clinicopathological features, n (%)

Clinicopathological feature	Total (n = 87)	TP53 mutant (n = 56)	TP53 wild-type (n = 31)	χ² value	P value
Tumor location				1.86	0.394
Left colon	21 (24.14)	11 (19.64)	10 (32.26)
Rectum	46 (52.87)	32 (57.14)	14 (45.16)
Right colon	20 (22.99)	13 (23.21)	7 (22.58)
Differentiation grade				1.93	0.165
Well/moderate	72 (82.76)	44 (78.57)	28 (90.32)
Poor	15 (17.24)	12 (21.43)	3 (9.68)
Lymphovascular invasion				10.63	0.001
Absent	51 (58.62)	40 (71.43)	11 (35.48)
Present	36 (41.38)	16 (28.57)	20 (64.52)
Perineural invasion				6.01	0.014
Absent	75 (86.21)	44 (78.57)	31 (100.00)
Present	12 (13.79)	12 (21.43)	0 (0.00)
Preoperative pathology				0.07	0.786
Adenocarcinoma (non-special)	82 (94.25)	52 (92.86)	30 (96.77)
Mucinous adenocarcinoma	5 (5.75)	4 (7.14)	1 (3.23)
T stage				1.52	0.218
T1 + T2	5 (5.75)	5 (8.93)	0 (0.00)
T3 + T4	82 (94.25)	51 (91.07)	31 (100.00)
N stage				0.00	1.000
N0	12 (13.79)	8 (14.29)	4 (12.90)
N1 + N2	75 (86.21)	48 (85.71)	27 (87.10)
M stage				1.76	0.184
M0	71 (81.61)	48 (85.71)	23 (74.19)
M1	16 (18.39)	8 (14.29)	8 (25.81)
Tumor number				4.38	0.036
Solitary	75 (86.21)	52 (92.86)	23 (74.19)
Multiple (≥ 2)	12 (13.79)	4 (7.14)	8 (25.81)
Maximum tumor diameter				2.49	0.114
< 5 cm	32 (36.78)	24 (42.86)	8 (25.81)
≥ 5 cm	55 (63.22)	32 (57.14)	23 (74.19)
Preoperative tumor markers				13.60	< 0.001
Normal	65 (74.71)	49 (87.50)	16 (51.61)
Elevated	22 (25.29)	7 (12.50)	15 (48.39)
Microsatellite				8.82	0.003
Microsatellite stable	81 (93.10)	56 (100.00)	25 (80.65)
Microsatellite instability	6 (6.90)	0 (0.00)	6 (19.35)